WallStSmart

Abbott Laboratories (ABT)vsBank of Montreal (BMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 32% more annual revenue ($44.33B vs $33.48B). BMO leads profitability with a 27.1% profit margin vs 14.7%. BMO appears more attractively valued with a PEG of 1.46. BMO earns a higher WallStSmart Score of 75/100 (B+).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

BMO

Strong Buy

75

out of 100

Grade: B+

Growth: 8.0Profit: 7.5Value: 10.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
BMOUndervalued (+57.3%)

Margin of Safety

+57.3%

Fair Value

$336.32

Current Price

$136.39

$199.93 discount

UndervaluedFair: $336.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

BMO6 strengths · Avg: 8.7/10
Operating MarginProfitability
39.9%10/10

Strong operational efficiency at 39.9%

Market CapQuality
$94.86B9/10

Large-cap with strong market position

Profit MarginProfitability
27.1%9/10

Keeps 27 of every $100 in revenue as profit

P/E RatioValuation
15.3x8/10

Attractively priced relative to earnings

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$6.95B8/10

Generating 7.0B in free cash flow

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BMO0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : BMO

The strongest argument for BMO centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 27.1% and operating margin at 39.9%. PEG of 1.46 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : BMO

No major red flags identified for BMO, but monitor valuation.

Key Dynamics to Monitor

ABT profiles as a value stock while BMO is a mature play — different risk/reward profiles.

BMO carries more volatility with a beta of 1.16 — expect wider price swings.

BMO is growing revenue faster at 10.0% — sustainability is the question.

BMO generates stronger free cash flow (7.0B), providing more financial flexibility.

Bottom Line

BMO scores higher overall (75/100 vs 51/100), backed by strong 27.1% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Bank of Montreal

FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA

Bank of Montreal offers diversified financial services primarily in North America. The company is headquartered in Montreal, Canada.

Want to dig deeper into these stocks?